ENTERA BIO LTD. Business Combination, Acquisition Related Costs
ENTERA BIO LTD. (ENTX) reported Business Combination, Acquisition Related Costs of $1.55 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:BusinessCombinationAcquisitionRelatedCosts · last filed 2026-08-07
- ENTERA BIO LTD. business combination, acquisition related costs for the quarter ending 2026-06-30 was $1.55M, a 159.43% increase year-over-year.
- ENTERA BIO LTD. business combination, acquisition related costs for the quarter ending 2026-03-31 was $780.00K, a 109.12% increase year-over-year.
- ENTERA BIO LTD. business combination, acquisition related costs for the quarter ending 2025-12-31 was $551.00K, a 29.34% increase year-over-year.
- ENTERA BIO LTD. business combination, acquisition related costs for the quarter ending 2025-09-30 was $572.00K, a 26.85% decline year-over-year.
- ENTERA BIO LTD. business combination, acquisition related costs for fiscal 2025 was $2.10M, a 54.04% increase from fiscal 2024.
- ENTERA BIO LTD. business combination, acquisition related costs for fiscal 2024 was $1.36M.
| Period end | Business Combination, Acquisition Related Costs 3 month | Business Combination, Acquisition Related Costs 6 month | Business Combination, Acquisition Related Costs 9 month | Business Combination, Acquisition Related Costs 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.55M 10-Q · filed 2026-08-07 | $2.33M 10-Q · filed 2026-08-07 | $2.88M derived: sum of 3 quarters · filed 2026-08-07 | $3.46M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $780.00K 10-Q · filed 2026-05-08 | $1.33M derived: sum of 2 quarters · filed 2026-05-08 | $1.90M derived: sum of 3 quarters · filed 2026-05-08 | $2.50M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $551.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $1.12M derived: sum of 2 quarters · filed 2026-03-27 | $1.72M derived: sum of 3 quarters · filed 2026-08-07 | $2.10M 10-K · filed 2026-03-27 |
| 2025-09-30 | $572.00K 10-Q · filed 2025-11-14 | $1.17M derived: sum of 2 quarters · filed 2026-08-07 | $1.54M 10-Q · filed 2025-11-14 | $1.97M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $599.00K 10-Q · filed 2026-08-07 | $972.00K 10-Q · filed 2026-08-07 | $1.40M derived: sum of 3 quarters · filed 2026-08-07 | $2.18M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $373.00K 10-Q · filed 2026-05-08 | $799.00K derived: sum of 2 quarters · filed 2026-05-08 | $1.58M derived: sum of 3 quarters · filed 2026-05-08 | $1.61M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $426.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $1.21M derived: sum of 2 quarters · filed 2026-03-27 | $1.24M derived: sum of 3 quarters · filed 2026-03-27 | $1.36M 10-K · filed 2026-03-27 |
| 2024-09-30 | $782.00K 10-Q · filed 2025-11-14 | $812.00K derived: sum of 2 quarters · filed 2025-11-14 | $934.00K 10-Q · filed 2025-11-14 | |
| 2024-06-30 | $30.00K 10-Q · filed 2025-08-08 | $152.00K 10-Q · filed 2025-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |